Inhibrxinc Stock Analysis

INBX Stock  USD 35.15  0.08  0.23%   
InhibrxInc is undervalued with Real Value of 38.35 and Target Price of 46.75. The main objective of InhibrxInc stock analysis is to determine its intrinsic value, which is an estimate of what InhibrxInc is worth, separate from its market price. There are two main types of InhibrxInc's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect InhibrxInc's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of InhibrxInc's stock to identify patterns and trends that may indicate its future price movements.
The InhibrxInc stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. InhibrxInc is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. InhibrxInc Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and InhibrxInc's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InhibrxInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy InhibrxInc Stock please use our How to Invest in InhibrxInc guide.

InhibrxInc Stock Analysis Notes

About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 5.12. InhibrxInc had not issued any dividends in recent years. Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. To learn more about InhibrxInc call the company at 858 795 4220 or check out https://inhibrx.com.

InhibrxInc Quarterly Total Revenue

1.63 Million

InhibrxInc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. InhibrxInc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding InhibrxInc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
InhibrxInc generated a negative expected return over the last 90 days
InhibrxInc has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M).
InhibrxInc currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52.
InhibrxInc has a frail financial position based on the latest SEC disclosures
Over 86.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 5954 shares by Brendan Eckelman of InhibrxInc at 28.9713 subject to Rule 16b-3

InhibrxInc Upcoming and Recent Events

Earnings reports are used by InhibrxInc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to InhibrxInc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

InhibrxInc Largest EPS Surprises

Earnings surprises can significantly impact InhibrxInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-12
2020-12-31-0.54-0.470.0712 
2021-05-13
2021-03-31-0.59-0.510.0813 
2023-03-06
2022-12-31-0.79-0.95-0.1620 
View All Earnings Estimates

InhibrxInc Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as InhibrxInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading InhibrxInc backward and forwards among themselves. InhibrxInc's institutional investor refers to the entity that pools money to purchase InhibrxInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Sofinnova Ventures2023-09-30
743.3 K
Capital Research Global Investors2023-12-31
712.4 K
Geode Capital Management, Llc2023-09-30
646.2 K
Soleus Capital Management, L.p.2023-09-30
549.2 K
Eventide Asset Management, Llc2023-09-30
434 K
Morgan Stanley - Brokerage Accounts2023-09-30
382.8 K
Jpmorgan Chase & Co2023-09-30
370 K
Northern Trust Corp2023-09-30
315.4 K
Two Sigma Advisers, Llc2023-09-30
310.2 K
Viking Global Investors Lp2023-09-30
7.2 M
Ra Capital Management, Llc2023-09-30
4.7 M
Note, although InhibrxInc's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

InhibrxInc Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate InhibrxInc's market, we take the total number of its shares issued and multiply it by InhibrxInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

InhibrxInc Profitablity

InhibrxInc's profitability indicators refer to fundamental financial ratios that showcase InhibrxInc's ability to generate income relative to its revenue or operating costs. If, let's say, InhibrxInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, InhibrxInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of InhibrxInc's profitability requires more research than a typical breakdown of InhibrxInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2024
Return On Capital Employed(0.87)(0.91)
Return On Assets(0.78)(0.82)
Return On Equity(5.55)(5.27)

Management Efficiency

InhibrxInc has return on total asset (ROA) of (0.4577) % which means that it has lost $0.4577 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7531) %, meaning that it created substantial loss on money invested by shareholders. InhibrxInc's management efficiency ratios could be used to measure how well InhibrxInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.91 in 2024. Return On Assets is likely to drop to -0.82 in 2024. At this time, InhibrxInc's Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 22.7 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 9.9 M in 2024.
Last ReportedProjected for 2024
Price Book Value Ratio 41.17  43.23 
Enterprise Value Multiple(7.90)(8.30)
Price Fair Value 41.17  43.23 
The analysis of InhibrxInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze InhibrxInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of InhibrxInc Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
2.945

Technical Drivers

As of the 28th of March, InhibrxInc retains the Market Risk Adjusted Performance of (1.21), downside deviation of 2.43, and Risk Adjusted Performance of 0.0752. InhibrxInc technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed nineteen technical drivers for InhibrxInc, which can be compared to its competitors. Please check out InhibrxInc information ratio, as well as the relationship between the potential upside and kurtosis to decide if InhibrxInc is priced fairly, providing market reflects its last-minute price of 35.15 per share. Given that InhibrxInc has jensen alpha of 0.3417, we strongly advise you to confirm InhibrxInc's regular market performance to make sure the company can sustain itself at a future point.

InhibrxInc Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. InhibrxInc middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for InhibrxInc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

InhibrxInc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific InhibrxInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on InhibrxInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases InhibrxInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

InhibrxInc Predictive Daily Indicators

InhibrxInc intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of InhibrxInc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

InhibrxInc Corporate Filings

F4
22nd of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
15th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
12th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
6th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
29th of February 2024
Other Reports
ViewVerify
10K
28th of February 2024
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
13A
14th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
6th of February 2024
Other Reports
ViewVerify

InhibrxInc Forecast Models

InhibrxInc's time-series forecasting models are one of many InhibrxInc's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary InhibrxInc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About InhibrxInc Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how InhibrxInc prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling InhibrxInc shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as InhibrxInc. By using and applying InhibrxInc Stock analysis, traders can create a robust methodology for identifying InhibrxInc entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin(133.18)(126.52)
Operating Profit Margin(121.79)(115.70)
Net Loss(134.09)(127.38)
Gross Profit Margin 0.34  0.36 

Current InhibrxInc Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. InhibrxInc analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. InhibrxInc analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
46.75Hold3Odds
InhibrxInc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most InhibrxInc analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand InhibrxInc stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of InhibrxInc, talking to its executives and customers, or listening to InhibrxInc conference calls.
InhibrxInc Analyst Advice Details

InhibrxInc Stock Analysis Indicators

InhibrxInc stock analysis indicators help investors evaluate how InhibrxInc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading InhibrxInc shares will generate the highest return on investment. By understating and applying InhibrxInc stock analysis, traders can identify InhibrxInc position entry and exit signals to maximize returns.
Begin Period Cash Flow273.9 M
Long Term Debt207 M
Common Stock Shares Outstanding47.1 M
Total Stockholder Equity43.5 M
Tax Provision3000.00
Property Plant And Equipment Net9.4 M
Cash And Short Term Investments277.9 M
Cash277.9 M
Accounts Payable11 M
Net Debt-67.8 M
50 Day M A36.4832
Total Current Liabilities56.3 M
Other Operating Expenses221 M
Non Current Assets Total12.5 M
Non Currrent Assets Other3.2 M
Stock Based Compensation24.8 M
When determining whether InhibrxInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of InhibrxInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inhibrxinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inhibrxinc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InhibrxInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy InhibrxInc Stock please use our How to Invest in InhibrxInc guide.
Note that the InhibrxInc information on this page should be used as a complementary analysis to other InhibrxInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for InhibrxInc Stock analysis

When running InhibrxInc's price analysis, check to measure InhibrxInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InhibrxInc is operating at the current time. Most of InhibrxInc's value examination focuses on studying past and present price action to predict the probability of InhibrxInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InhibrxInc's price. Additionally, you may evaluate how the addition of InhibrxInc to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bonds Directory
Find actively traded corporate debentures issued by US companies
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is InhibrxInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InhibrxInc. If investors know InhibrxInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InhibrxInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.12)
Revenue Per Share
0.038
Quarterly Revenue Growth
4.964
Return On Assets
(0.46)
Return On Equity
(4.75)
The market value of InhibrxInc is measured differently than its book value, which is the value of InhibrxInc that is recorded on the company's balance sheet. Investors also form their own opinion of InhibrxInc's value that differs from its market value or its book value, called intrinsic value, which is InhibrxInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InhibrxInc's market value can be influenced by many factors that don't directly affect InhibrxInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InhibrxInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if InhibrxInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InhibrxInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.